

PERSONAL

Jeffrey B. Ulmer

Department of Vaccines Research, Novartis Vaccines & Diagnostics,
350 Massachusetts Ave., Cambridge, MA 02139

Tel: (617) 871-8183, Fax: (617) 871-8759, e-mail: jeffrey.ulmer@novartis.com

EDUCATION

<u>School</u>	<u>Date</u>	<u>Major/Minor</u>	<u>Degree</u>
McGill University	1985	Biochemistry	Ph.D.
Luther College, Univ. of Regina	1978	Biochemistry/Chemistry	B.Sc. (Honors)

ACADEMIC AND PROFESSIONAL HONORS

1983	Hugh Edmund Burke Medical Research Award
1981	Multiple Sclerosis Society of Canada Postgraduate Scholarship
1980	Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship
1978	Graduated with Distinction
1978	Society of Chemical Industry Merit Award

PROFESSIONAL RESEARCH AND MANAGEMENT EXPERIENCE

2008	Global Head, External Research, Novartis Vaccines & Diagnostics.
2007	Site Head US, Vaccines Research, Novartis Vaccines & Diagnostics.
2006	Head, Immunology and Cell Biology, Novartis Vaccines & Diagnostics.
2003	Head, Immunology and Cell Biology, Chiron Vaccines.
2000	Senior Director, Vaccines Research, Chiron Corporation.
1998	Director, Vaccines Research, Chiron Corporation.
1996	Senior Research Fellow, Department of Virus and Cell Biology, Merck Research Laboratories.
1993	Research Fellow, Department of Virus and Cell Biology, Merck Research Laboratories.
1990	Senior Research Biochemist, Department of Cancer Research, Merck Research Laboratories.
1988	Associate Research Scientist, Department of Cell Biology, Yale University School of Medicine.
1985	Postdoctoral Fellow, Preceptor: Dr. George E. Palade, Department of Cell Biology, Yale University School of Medicine.
1980	Doctoral Trainee, Preceptor: Dr. Peter E. Braun, Department of Biochemistry, McGill University.
1978	Assistant in Research, Principal Investigator: Dr. J.R. Gear, Department of Chemistry, University of Regina.

SOCIETY MEMBERSHIPS

1990 - present	American Society for Cell Biology
1999 - present	European Society of Clinical Microbiology and Infectious Diseases
2002 - present	Controlled Release Society

ACADEMIC RESEARCH EXPERIENCE

My doctoral research involved the biogenesis of myelin, where I specifically studied the post-translational modification of one of the major membrane-associated proteins, myelin basic protein (MBP). Phosphorylation was demonstrated to serve two functions: (i) a role in targeting nascent MBPs to the specific site(s) on the oligodendrocyte plasmalemma where myelin proliferation is being initiated, and (ii) a maintenance function in the intact sheath.

I conducted postdoctoral research with Nobel Laureate Dr. George Palade at Yale University School of Medicine, where I studied translocation of proteins across membranes and intracellular trafficking, which are areas of high current interest in biology. Specifically, I studied the translocation of nascent polypeptides across the endoplasmic reticulum (ER) membrane, their subsequent transport from the ER to the Golgi complex, and the modifications of proteins that take place during this transit. I determined the nature and intracellular locations of glycoprotein glycosylation, fatty acid acylation and phosphorylation, and discovered that trafficking was anomalous with respect to translocation across the ER membrane. In addition, I contributed to the early characterization of the membrane traffic perturbant, brefeldin A, which is now a commonly used tool in biology.

PREVIOUS INDUSTRIAL RESEARCH EXPERIENCE

At Merck Research Laboratories, I contributed significantly to three research programs. Initially, I investigated the mitogenicity of the major immunoenhancing protein of *Neisseria meningitidis* and discovered a relationship between pore formation and mitogenicity of this protein. Shortly thereafter, I directed one postdoctoral scientist and one technician in elucidating the intracellular processing events involved in the targeting of exogenous toxin-antigen fusion proteins to intracellular MHC class I molecules. This program resulted in the elucidation of a pathway of antigen presentation involving recycling of cell surface MHC Class I molecules, thereby suggesting a novel means of inducing cytotoxic T lymphocyte responses against viral antigens.

Most of my efforts at Merck were in the DNA vaccine programs, where I conducted seminal proof of concept studies demonstrating induction of CTL responses and protective efficacy in animal models of infection. Subsequently, I directed various aspects of the research that expanded the utility of this approach as a powerful new means of vaccination. For these contributions, I was named one of the key innovators in Merck's influenza DNA vaccine program. I then established the tuberculosis DNA vaccine program where we expanded the applicability of the technology to non-viral infectious disease targets as well. My group was responsible for: i) preclinical studies on influenza, tuberculosis, and HIV DNA vaccines, ii) elucidation of the underlying mechanisms of induction of immune responses by DNA vaccination, iii) development of next generation DNA vaccines through the use of vaccine adjuvants and delivery systems, and iv) development of an influenza DNA vaccine for human clinical evaluation. At Merck Research Laboratories, I directed the research efforts of eight scientists (2 Ph.D., 1 M.D., 1 M.S., 4 B.S.) in the areas of immunology, virology, cell biology and molecular biology. During this time, I was an advisor to the World Health Organization Steering Committee on the Immunology of Mycobacteria.

RECENT MANAGEMENT RESPONSIBILITIES

At Novartis Vaccines and Diagnostics, I served as the Site Head for US Vaccines Research, Emeryville, CA reporting to the Global Head of Research. I directed a diverse group of >75 scientists in immunology, cell biology, virology, and molecular biology; working in the areas of viral vaccine discovery and technology development. I also directed a grants and contracts management group responsible for preparation, submission, negotiation and management of external contracts. From 1999 to 2006, my group managed >\$500 million in completed, active and pending awards from government and non-government sources.

I am currently Global Head of External Research based in Cambridge, MA with responsibility for creating new strategies and opportunities for external collaborations in all aspects of the vaccines discovery and development process.

SCIENTIFIC PUBLICATIONS

1. Ulmer, J.B. 1978. "The biosynthesis of chelidonic acid". Honours Thesis, Department of Chemistry, University of Regina, Regina, Canada.
2. Ulmer, J.B. and Braun, P.E. 1984. "*In vivo* phosphorylation of myelin basic proteins in developing mouse brain: Evidence that phosphorylation is an early event in myelin formation". **Dev. Neurosci.** 6, 345-355.
3. Ulmer, J.B. 1985. "The phosphorylation of myelin basic proteins and its relevance to myelin biogenesis". Ph.D. Thesis, Department of Biochemistry, McGill University, Montreal, Canada.
4. Ulmer, J.B. and Braun, P.E. 1986. "*In vivo* phosphorylation of myelin basic proteins: Age-related differences in ^{32}P incorporation". **Dev. Biol.** 117, 493-501.
5. Ulmer, J.B. and Braun, P.E. 1986. "*In vivo* phosphorylation of myelin basic proteins: Single and double isotope incorporation in developmentally-related myelin fractions". **Dev. Biol.** 117, 502-510.
6. Ulmer, J.B., Edwards, A.M., McMorris, F.A. and Braun, P.E. 1987. "Cyclic AMP decreases the phosphorylation state of myelin basic proteins in rat brain cell cultures". **J. Biol. Chem.** 262, 1748-1755.
7. Ulmer, J.B. and Braun, P.E. 1987. "Chloroform markedly stimulates the phosphorylation of myelin basic proteins". **Biochem. Biophys. Res. Commun.** 146, 1084-1088.
8. Ulmer, J.B. 1988. "The phosphorylation of myelin proteins". **Progress in Neurobiology** 31, 241-259.
9. Edwards, A.M., Ross, N.W., Ulmer, J.B. and Braun, P.E. 1989. "Interaction of myelin basic protein and proteolipid protein". **J. Neurosci. Res.** 22, 97-102.
10. Ulmer, J.B. and Palade, G.E. 1989. "Anomalies in the translocation and processing of glycophorin precursors in murine erythroleukemia cells". **J. Biol. Chem.** 264, 1084-1091.
11. Ulmer, J.B., Dolci, E.D. and Palade, G.E. 1989. "Glycophorin expression in murine erythroleukaemia cells". **J. Cell Sci.** 92, 163-171.
12. Ulmer, J.B. and Palade, G.E. 1989. "Targeting and processing of glycophorins in murine erythroleukemia cells: Use of brefeldin A as a perturbant of intracellular traffic". **Proc. Natl. Acad. Sci. USA** 86, 6992-6996.
13. Schnitzer, J.E., Ulmer, J.B. and Palade, G.E. 1990. "A major endothelial sialoglycoprotein, gp60, is immunologically related to glycophorin". **Proc. Natl. Acad. Sci. USA** 87, 6843-6847.
14. Ulmer, J.B. and Palade, G.E. 1991. "Effects of brefeldin A on the Golgi complex, endoplasmic reticulum and viral envelope glycoproteins in murine erythroleukemia cells". **Eur. J. Cell Biol.** 54, 38-54.
15. Ulmer, J.B. and Palade, G.E. 1991. "Effects of brefeldin A on the processing of viral envelope glycoproteins in murine erythroleukemia cells". **J. Biol. Chem.** 266, 9173-9179.
16. Schnitzer, J.E., Ulmer, J.B., and Palade, G.E. 1992. "Common peptide epitopes in glycophorin and the endothelial sialoglycoprotein gp60". **Biochem. Biophys. Res. Commun.** 187, 1158-1165.
17. Ulmer, J.B., Burke, C.J., Shi, C.-Y., Friedman, A., Donnelly, J.J., and Liu, M.A. 1992. "Pore formation and mitogenicity in blood cells by the class 2 protein of *Neisseria meningitidis*". **J. Biol. Chem.** 267, 19266-19271.
18. Ulmer, J.B., Donnelly, J.J., Parker, S.E., Rhodes, G.H., Felgner, P.L., Dwarki, V.J., Gromkowski, S.H., Deck, R.R., DeWitt, C.M., Friedman, A., Hawe, L.A., Leander, K.R.,

- Martinez, D., Perry, H.C., Shiver, J.W., Montgomery, D.L., and Liu, M.A. 1993. "Heterologous protection against influenza by injection of DNA encoding a viral protein". **Science** 259, 1745-1749.
19. Donnelly, J.J., Ulmer, J.B., Hawe, L.A., Friedman, A., Shi, X.-P., Leander, K.R., Shiver, J.W., Oliff, A.I., Martinez, D., Montgomery, D.L., and Liu, M.A. 1993. "Targeted delivery of peptide epitopes to MHC class I by a modified *Pseudomonas* exotoxin". **Proc. Natl. Acad. Sci. USA** 90, 3530-3534.
 20. Liu, M.A., Ulmer, J.B., Friedman, A., Martinez, D., DeWitt, C.M., Leander, K.R., Shi, X.-P., Parker, S., Felgner, P., Felgner, J., Montgomery, D.L., and Donnelly, J.J.. 1993. "Immunization with DNA encoding a conserved internal viral protein results in protection from morbidity and mortality due to challenge with influenza A in mice". In, **Vaccines 93**, ed., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 343-346.
 21. Deck, R.R., Donnelly, J.D., Hawe, L.A., Friedman, A., Ulmer, J.B., and Liu, M.A. 1993. "Class 2 outer membrane protein from *Neisseria meningitidis* induces immunoglobulin secretion by murine B lymphocytes". In, **Vaccines 93**, ed., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 359-363.
 22. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1993. "Polynucleotide vaccines". **Curr. Opin. Invest. Drugs** 2, 983-989.
 23. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1993. "Immunization with naked DNA: a sexy technique", reply. **Gastroenterol.** 105, 1252-1253.
 24. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1993. "Naked DNA and vaccine design", reply. **Trends Microbiol.** 1, 324-325.
 25. Montgomery, D.L., Shiver, J.W., Leander, K.R., Perry, H.C., Friedman, A., Martinez, D., Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1993. "Heterologous and homologous protection against influenza A by DNA vaccination: Optimization of vectors". **DNA Cell Biol.** 12, 777-783.
 26. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1994. "Presentation of an exogenous antigen by major histocompatibility class I molecules". **Eur. J. Immunol.** 24, 1590-1596.
 27. Ulmer, J.B., Deck, R.R., DeWitt, C.M., Friedman, A., Donnelly, J.J., and Liu, M.A. 1994. "Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines". **Vaccine** 12, 1541-1544.
 28. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1994. "Immunization with polynucleotides: A novel approach to vaccination". **The Immunologist** 2, 20-26.
 29. Montgomery, D., Leander, K.R., Shiver, J.W., Perry, H., Friedman, A., Martinez, D., Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1994. "Nonreplicating DNA vectors designed to generate heterologous and homologous protection against influenza". In, **Vaccines 94**, ed., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 61-64.
 30. Donnelly, J.J., Friedman, A., Montgomery, D., Shiver, J.W., Leander, K.R., Perry, H., Martinez, D., Ulmer, J.B. and Liu, M.A. 1994. "Polynucleotide vaccination against influenza". In, **Vaccines 94**, ed., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY. pp. 55-59.

31. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1994. "Vaccination with polynucleotides: A novel means of generating immunity". In, **Modern Vaccinology**, ed. Kurstak, E., Plenum Medical Book Co., New York, NY. pp. 13-23.
32. Montgomery, D.L., Donnelly, J.J., Shiver, J.W., Liu, M.A., and Ulmer, J.B. 1994. "Protein expression in vivo by injection of polynucleotides". **Curr. Opin. Biotechnol.** 5, 505-510.
33. Donnelly, J.J., Ulmer, J.B. and Liu, M.A. 1994. "Immunization with DNA". **J. Immunol. Meth.** 176, 145-152.
34. Donnelly, J.J., Friedman, A., Martinez, D., Montgomery, D.L., Shiver, J.W., Motzel, S., Ulmer, J.B., Liu, M.A. 1995. "Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus". **Nature Med.** 1, 583-587.
35. Deck, R.R., DeWitt, C.M., Donnelly, J.J., Liu, M.A., and Ulmer, J.B. 1995. "Humoral immune responses to influenza hemagglutinin by DNA vaccination". In, **Vaccines 95**, eds., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY), pp. 91-94.
36. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1995. "Recombinant vaccines: Technology and applications". **Exp. Opin. Ther. Patents** 5, 211-217.
37. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1995. "Protective efficacy of intramuscular immunization with naked DNA". **Ann. NY Acad. Sci.** 772, 40-46.
38. Ulmer, J.B., Donnelly, J.D., Deck, R.R., DeWitt, C.M., and Liu, M.A. 1995. "Immunization with naked DNA." **Ann. NY Acad. Sci.** 772, 117-125.
39. Ulmer, J.B., Deck, R.R., Yawman, A.M., Friedman, A., DeWitt, C.M., Martinez, D., Donnelly, J.D., and Liu, M.A. 1996. "DNA vaccines for bacteria and viruses". **Adv. Exp. Med. Biol.** 397, 49-53.
40. Ulmer, J.B., Montgomery, D.L., Donnelly, J.J., and Liu, M.A. 1996. "DNA vaccines". In, **Methods Molecular Medicine: Vaccine Protocols**, eds., Robinson, A, Farrar, G.H., Wiblin, C.N., Humana Press (Totowa, NJ), pp. 289-300.
41. Ulmer, J.B., Donnelly, J.J., Shiver, J.W., and Liu, M.A. 1996. "Prospects for the induction of mucosal immunity by DNA vaccines". In, **Mucosal Vaccines**, eds., Kiyono, H., Ogra, P., McGhee, J., Academic Press, Inc., San Diego, CA pp. 119-127.
42. Shiver, J.W., Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1996. "Naked DNA vaccination". In, **Concepts in Vaccine Design**, ed, Kaufmann, S., Walter DeGruyter & Co., Berlin, pp. 423-436.
43. Ulmer, J.B., Liu, M.A., Montgomery, D.L., Denis, O., Yawman, A.M., Drowart, A., Lozes, E., Vandenbussche, P., Van Vooren, J.-P., DeWitt, C.M., Deck, R.R., Content, J., and Huygen, K. 1996. "Immunogenicity and efficacy of a tuberculosis DNA vaccine". In, **Vaccines 96**, eds., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY.), pp. 39-44.
44. Liu, M.A., Caulfield, M.J., Donnelly, J.J., DeWitt, C.M., Deck, R.R., and Ulmer, J.B. 1996. "Mechanisms of protective immunity for an influenza DNA vaccine". In, **Vaccines 96**, eds., Brown, F., Chanock, R.M., Ginsberg, M.S., Lerner, R.A., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY.), pp. 79-82.
45. Ulmer, J.B., and Liu, M.A. 1996. ELI's Coming: Expression library immunization (ELI) as a potential means of vaccine antigen discovery". **Trends Microbiol.** 4, 169-170.
46. Huygen, K., Content, J., Denis, O., Montgomery, D.L., Yawman, A.M., R.R. Deck, DeWitt, C.M., Orme, I.M., Baldwin, D'Souza, C., S., Drowart, A., Lozes, E., Vandenbussche, P.,

- Mooren, J.-P., Liu, M.A., and Ulmer J.B. 1996. "Immunogenicity and protective efficacy of a tuberculosis DNA vaccine". **Nature Med.** 2, 893-898.
47. Ulmer, J.B., Deck, R.R., DeWitt, C.M., Donnelly, J.J., and Liu, M.A. 1996. "Generation of MHC class I-restricted cytotoxic T lymphocytes by expression of a viral protein in muscle cells: Antigen presentation by non-muscle cells ". **Immunol.** 89, 59-67.
48. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. "DNA vaccines". 1996. **ASM News** 62, 476-479.
49. Shiver, J.W., Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1996. "Humoral and cellular immunities elicited by DNA vaccines: Application to the human immunodeficiency virus and influenza". **Adv. Drug Del. Rev.** 21, 19-31.
50. Ulmer, J.B. and Liu, M.A. 1996. "Prospects for the development of a tuberculosis DNA vaccine". **The Jordan Report** pp. 59-62.
51. Ulmer, J.B., Sadoff, J.C., and Liu, M.A. 1996. "DNA vaccines". **Curr. Opin. Immunol.** 8, 531-536.
52. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1996. "Toward the development of DNA vaccines". **Curr. Opin. Biotechnol.** 7, 653-658.
53. Donnelly, J.J., Fu, T.-M., Friedman, A., Caulfield, M.J., Ulmer, J.B., and Liu, M.A. 1996. "Further investigations on the potential utility of DNA vaccines for influenza", In **Options for the Control of Influenza III**, eds. L.F. Brown, A.W. Hampson and R.G. Webster, Elsevier Science B.V., pp. 777-781.
54. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1997. "DNA vaccines". **Life Sci.** 60, 163-172.
55. Deck, R.R., DeWitt, C.M., Donnelly, J.J., Liu, M.A., and Ulmer, J.B. 1997. "Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine". **Vaccine** 15, 71-78.
56. Ulmer, J.B., Donnelly, J.D., and Liu, M.A. 1997. "DNA vaccines: A new category". In, **Veterinary Vaccinology**, eds. Pastoret, P.-P., Blancou, J., Vannier, P., Verschueren, C., Elsevier (New York, NY), pp. 285-291.
57. Donnelly, J.J., Ulmer, J.B., Shiver, J.W., and Liu, M.A. 1997. "DNA vaccines". **Ann. Rev. Immunol.** 15, 617-648.
58. Fu, T.-M., Friedman, A., Ulmer, J.B., Liu, M.A., and Donnelly, J.J. 1997. "Protective cellular immunity: CTL responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA vaccination". **J. Virol.** 71, 2715-2721.
59. Donnelly, J.J., Friedman, A., Deck, R.R., DeWitt, C.M., Caulfield, M.J., Liu, M.A. and Ulmer, J.B. 1997. "Adjuvant effects of DNA vaccines". In, **Vaccines 97**, eds., Brown, F., Burton, F., Doherty, P., Mekalanos, J., Norrby, E., Cold Spring Harbor Laboratory Press (Cold Spring Harbor, NY), pp. 105-111.
60. Liu, M.A., McClements, W., Ulmer, J.B., Shiver, J., and Donnelly, J.J. 1997. "Immunization of primates with DNA vaccines". **Vaccine** 15, 909-912.
61. Lozes, E., Huygen, K., Content, J., Denis, O., Montgomery, D.L., Yawman, A.M., Vandenbussche, P., Van Vooren, J.-P., Drowart, A., Ulmer, J.B., and Liu, M.A. 1997. "Immunogenicity and efficacy of a tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex". **Vaccine** 15, 83-833.
62. Ulmer, J.B., Deck, R.R., DeWitt, C.M., Fu, T.-M., Donnelly, J.J., Caulfield, M.J., and Liu, M.A. 1997. "Expression of a viral protein in muscle cells in vivo induces protective cell-mediated immunity". **Vaccine** 15, 839-841.

63. Ulmer, J.B., Liu, M.A., Montgomery, D.L., Yawman, A.M., Deck, R.R., DeWitt, C.M., Content, J., and Huygen, K. 1997. "Expression and immunogenicity of *M. tuberculosis* antigen 85 by DNA vaccination". **Vaccine** 15, 792-794.
64. Ulmer, J.B., Deck, R.R., DeWitt, C.M., Donnelly, J.J., Friedman, A., Montgomery, D.L., Yawman, A.M., Orme, I.M., O. Denis, Content, J., Huygen, K., and Liu, M.A. 1997. "Induction of immunity by DNA vaccination: Application to influenza and tuberculosis". **Behr. Inst. Mitt.** 98, 79-86.
65. Donnelly, J.J., Friedman, A., Ulmer, J.B., and Liu, M.A. 1997. "Further protection against antigenic drift of influenza virus in a ferret model with a DNA vaccine". **Vaccine** 15, 865-868.
66. Montgomery, D.L., Huygen, K., Yawman, A.M., Deck, R.R., DeWitt, C.M., Content, J., Liu, M.A., and Ulmer, J.B. 1997. Induction of humoral and cellular immune responses by vaccination with *M. tuberculosis* antigen 85 DNA". **Cell Mol. Biol.** 43, 285-292.
67. Montgomery, D.L., Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1997. "DNA vaccines". **Pharmacol. Ther.** 74, 195-205.
68. Ulmer, J.B. 1997. Book reviews on "Targeting of Drugs, 5. Strategies for Oligonucleotide and Gene Delivery in Therapy" and "Artificial Self-Assembling Systems for Gene Delivery". **Pharm. Res.** 14, 953.
69. Fu, T.-M., Ulmer, J.B., Caulfield, M.J., Deck, R.R., Friedman, A., Wang, S., Liu, X., Donnelly, J.J., and Liu, M.A. 1997. "Priming of cytotoxic T lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes". **Mol. Med.** 3, 362-371.
70. Ulmer, J.B. 1997. Research News on "Elegantly presented DNA vaccines". **Nature Biotechnol.** 15, 842-843.
71. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1997. "Vaccination against Influenza with Plasmid DNA: cross-strain and homologous protection". In, **New Generation Vaccines** eds., Levine, Myron M., Woodrow, Graeme C., Kaper, James B. and Cobon, Gary S., Marcel Dekker, Inc. (New York, NY), pp. 287-295.
72. Ulmer, J.B., Donnelly, J.J., Montgomery, D.L., and Liu, M.A. 1998. "Art and science of DNA vaccines". **Meth. Microbiol.** 25, 459-469.
73. Ulmer, J.B., Montgomery, D.L., Tang, A., Zhu, L., Deck, R.R., DeWitt, C.M., O. Denis, Orme, I., Content, J., and Huygen, K. 1998. "DNA vaccines against tuberculosis". In, **Novartis Foundation Symposium 217, Genetics and Tuberculosis** (John Wiley & Sons, Chichester), pp. 239-253.
74. Denis, O., Tanghe, A., Palfliet, K., Jurion, F., van den Berg, T.-P., Vanonckelen, A., Ooms, J., Saman, E., Ulmer, J.B., Content, J., and Huygen, K. 1998. "Vaccination with plasmid DNA encoding Ag85A stimulates a broader CD4+ and CD8+ T cell epitopic repertoire than infection with *M. tuberculosis* H37Rv". **Infect. Immunity** 66, 1527-1533.
75. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1998. DNA vaccines. In **Preclinical and Clinical Development of New Vaccines, Developments in Biological Standardization**, Vol. 95, Proceedings of a Symposium organized and sponsored by the Institut Pasteur and the International Association of Biological Standardization, Paris, France, May 27-28, 1997, eds. Plotkin, S.A., Brown, F., Haraud, F., Karger (Basel), pp. 43-53.
76. Baldwin, S.L., D'Souza, C., Roberts, A.D., Kelly, B.P., Frank, A.A., Huygen, K., Liu, M.A., Ulmer, J.B., McMurray, D.M., Or me, I.M. 1998. "Evaluation of new vaccines in mouse and guinea pig models of tuberculosis". **Infect. Immunity** 66, 2951-2959.

77. Ulmer, J.B., T.-M. Fu, R.R. Deck, A. Friedman, L. Guan, C.M. DeWitt, X. Liu, S. Wang, M. A. Liu, J. J. Donnelly, and M. J. Caulfield. 1998. "Protective CD4+ and CD8+ T cells against influenza induced by vaccination with nucleoprotein DNA". **J. Virol.** 72, 5648-5653.
78. Bender, B.S., J.B. Ulmer, C.M. DeWitt, R. Cottey, S.F. Taylor, M.A. Liu, and J.J. Donnelly. 1998. "Immunogenicity and efficacy of DNA vaccines encoding influenza A proteins in aged mice". **Vaccine** 16, 1748-1755.
79. Fu, T.-M., L. Guan, A. Friedman, J.B. Ulmer, M.A. Liu, and J.J. Donnelly. 1998. "Induction of MHC class I-restricted CTL response by DNA immunization with ubiquitin-influenza virus nucleoprotein fusion antigens". **Vaccine** 16, 1711-1717.
80. Selby, M., C.M. Walker, and J.B. Ulmer. 1998. "Mechanisms of action of DNA vaccines". **Exp. Opin. Invest. Drugs** 7, 1987-1995.
81. Donnelly, J.J., Ulmer, J.B., and Liu, M.A. 1998. DNA vaccines. In **Bacterial Protein Toxins** (Eighth European Workshop, Staffelstein, Kloster Banz, Germany, June 29 to July 4, 1997), International Journal of Medical Microbiology, Virology, Parasitology and Infectious Diseases, Supplement 29, eds. Hacker, J., Alouf, J.E., Brand, B.C., Falmagne, P., Fehrenback, F.J., Freer, J.H., Goebel, W., Gross, R., Heesemann, J., Locht, C., Montecucco, C., Olsnes, S., Rappuoli, R., Reidl, J., Wadström, T., Gustav Fischer (Jena, Germany), pp. 428-436.
82. Liu M.A., Fu T.-M., Donnelly J.J., Caulfield M.J., and Ulmer J.B. 1998. DNA vaccines: Mechanisms for generation of immune responses. **Adv. Expt. Med. Biol.** 452, 187-191.
83. Baldwin, S.L., D'Souza, C.D., Orme, I.M., Liu, M.A., Huygen, K., Denis, O., Tang, A., Zhu, L., Montgomery, D.L., and Ulmer, J.B. 1999. "Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of M. tuberculosis Ag85A". **Tubercle Lung Dis.** 79, 251-259.
84. Fu, T.-M., L. Guan, A. Friedman, J.B. Ulmer, M.A. Liu, and J.J. Donnelly. 1999. "Dose-dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge". **J. Immunol.** 162, 4163-4170.
85. Ulmer, J.B., and M.A. Liu. 1999. "Delivery systems and adjuvants for DNA vaccines. In, **The Development of Gene Therapy**, ed.T. Friedmann, Cold Spring Harbor Laboratory Press, (Cold Spring Harbor , NY) pp. 309-330.
86. Ulmer, J.B., C.M. DeWitt, M. Chastain, A. Friedman, J.J. Donnelly, W. McClements, M.J. Caulfield, K. Bohannon, D. Volkin, and R. Evans. 1999. "Enhancement of DNA vaccine potency using conventional aluminum adjuvants". **Vaccine** 18, 18-28.
87. Ulmer, J.B. and J.J. Donnelly. 1999. "Vaccines: DNA". **Encyclopedia of Life Sciences**. (on-line at <http://www.els.net>).
88. Ulmer, J.B., Donnelly, J.J., and Liu, M.A. 1999. DNA vaccines: Immunogenicity and preclinical efficacy. **Vaccines: Handbook Exp. Pharmacol.** 133, 43-56.
89. Dietrich, G., Gentshev, I., Hess, J., Ulmer, J.B., Kaufmann, S.H.E., and Goebel, W. 1999. "Delivery of DNA vaccines by attenuated intracellular bacteria". **Immunol. Today** 20, 251-254.
90. Donnelly J.J., and Ulmer, J.B. 1999. "DNA vaccines for viral diseases." **Brazilian J. Med. Biol. Res.** 32, 15-222.
91. Wang, S., X. Liu, K. Fisher, J.G. Smith, T.W. Tobery, J.B. Ulmer, R.K. Evans and M.J. Caulfield. 2000. "Enhanced type I immune response to a hepatitis B DNA vaccine by formulation with calcium or aluminum phosphate". **Vaccine** 18, 1227-1235.

92. Lee, A.Y., Otten, G.R., Ulmer, J.B., Houghton, M., and Paliard, X. 2000. "Quantification of the number of cytotoxic T cells for an immunodominant HCV-specific CTL epitope primed by DNA vaccination". **Vaccine** 18, 1962-1968.
93. Widera, G., Austin, M., Rabussay D., Goldbeck, C., Barnett, S., Chen, M., Leung, L., Otten, G.R., Thudium, K., Selby, M.J., and Ulmer, J.B. 2000. "Increased DNA vaccine delivery and immunogenicity by electroporation in vivo." **J. Immunol.** 164, 4635-4640.
94. Ulmer, J.B. and Liu, M.A. 2000. "Gene-based vaccines". **Mol. Therapy** 1, 396-399.
95. Lee, A.Y., Manning, W.C., Arian, C.L., Polakos N.K., Barajas J.L., Ulmer, J.B., Houghton, M., and Paliard, X. 2000. "Priming of hepatitis C virus-specific cytotoxic T lymphocytes in mice following portal vein injection of a liver-specific plasmid DNA". **Hepatology** 31, 1327-1333.
96. Selby, M., Goldbeck, C., Pertile, T., Walsh, R., and Ulmer, J.B. 2000. Enhancement of DNA vaccine potency by electroporation". **J. Biotechnol.** 83, 147-152.
97. Ulmer, J.B. and Otten, G.R. 2000. "Priming of CTL responses by DNA vaccines: Direct transfection of antigen presenting cells versus cross-priming." **Developments in Biologicals** 104, 9-14.
98. Dupuis, M., Denis-Mize, K., Woo, C., Goldbeck, C., Selby, M.J., Ulmer, J.B., Donnelly, J.J., Ott, G., and MacDonald, D.M. 2000. "Distribution of DNA vaccines determines their immunogenicity after intramuscular injection in mice". **J. Immunol.** 165, 2850-2858.
99. Dubensky, T.W., Liu, M.A., and Ulmer, J.B. 2000. "Delivery systems for gene-based vaccines." **Mol. Medicine** 6, 723-732.
100. Denis-Mize, K.S., Dupuis, M., MacKichan, M.L., Singh, M., O'Hagan, D., Ulmer, J.B., Donnelly, J., MacDonald, D., and Ott, G. 2000. "Plasmid DNA adsorbed onto PLG-CTAB microparticles mediates target gene expression and antigen presentation by dendritic cells". **Gene Therapy** 7, 2105-2112.
101. Donnelly, J.J., Liu, M.A., and Ulmer, J.B. 2000. "Antigen presentation and DNA vaccines." **Am. J. Resp. Crit. Care Med.** 162, S190-S193.
102. Otten, G.R., Doe, B., Schaefer, M., Chen, M., Selby, M.J., Goldbeck, C., Hong, M., Xu, F., Ulmer, J.B. 2001. "Relative potency of cellular and humoral immune responses by DNA vaccination". **Intervirology** 43, 227-232.
103. Ulmer, J.B. 2001. "Tuberculosis DNA vaccines". **Scand. J. Infect. Dis.** 33, 246-248.
104. Ulmer, J.B. 2001. "An update on the state of the art of DNA vaccines". **Curr. Opin. Drug Discovery Dev.** 4, 192-197.
105. Barnett, S.W., Lu, S., Srivastava, I., Cherpelis, S., Gettie, A., Blanchard, J., Wang, S., Mboudjeka, I., Leung, L., Yian, Y., Fong, A., Buckner, C., Ly, A., Hilt, S., Ulmer, J.B., Wild, C.T., Mascola, J.R., and Stamatatos, L. 2001. "The ability of an oligomeric HIV-1 envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following the partial deletion of the second hypervariable region." **J. Virol.** 75, 5526-5540.
106. O'Hagan, D., Singh, M., Ugozzoli, M., Wild, C., Barnett, S., Chen, M., Schaefer, M., Doe, B., Otten, G.R., and Ulmer, J.B. 2001. "Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines". **J. Virol.** 75, 9037-9045.
107. Ulmer, J.B. 2002. "Towards the development of better vaccine adjuvants". **Exp. Opin. Biol. Therapy** 2, 119-121.
108. Srivastava, I., Stamatatos, L., Fong, A., Legg, H., Kan, E., Coates, S., Leung, L., Wininger, M., Tipton, A.R., Ulmer, J.B., and Barnett, S.W. 2002. "Purification and characterization of

- oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus for vaccine applications". **J. Virol.** 76, 2835-2847.
109. Ulmer, J.B. and Liu, M.A. 2002. "Ethical issues for vaccines and immunization". **Nature Reviews Immunol.** 2, 291-296.
110. Ulmer, J.B. 2002. "Influenza DNA vaccines". **Vaccine** 20, S74-S76.
111. Ulmer, J.B. 2002. "Gene-based vaccines – Keystone Symposium: Mechanisms, delivery systems and efficacy. Meeting report." **Investigational Drug J.** 5, 514-516.
112. Ulmer, J.B. 2002. "DNA vaccines against RNA viruses". In **DNA Vaccines**, ed. Ertl, H.C., Plenum Publishers, New York, NY, pp. 112-126.
113. Liu, M.A., Ulmer, J.B., and O'Hagan, D. 2002. "Vaccine technologies", **Jordan Report** pp. 31-37.
114. Xu, F., Hong, M. and Ulmer, J.B. 2003. "Immunogenicity of an HIV-1 gag DNA vaccine carried by attenuated *Shigella*". **Vaccine** 21, 644-648.
115. Otten, G.R., Chen, M., Doe, B., zur Megede, J., Barnett, S. and Ulmer, J.B. 2003. "Quantitative assessment of antigen-specific CD8+ T cells in the mouse: application to vaccines research". **Immunol. Lett.** 85, 215-222.
116. Pasetti, M.F., Losonsky, G., Barry E.M., Singh, M., Medina-Moreno, S.M., Polo, J., Ulmer, J.B., Robinson, H., Sztein, M.B., and Levine, M.M. 2003. "Attenuated *Salmonella enterica* serovar Typhi and *Shigella flexneri* 2A strains are effective mucosal delivery vehicles for DNA vaccines encoding measles virus hemagglutinin, inducing specific immune responses and protection in cotton rats". **J. Virol.** 77, 5209-5217.
117. Luo, Y., O'Hagan, D., Niethammer, A.G., Zhou, H., Singh, M., Ulmer, J.B., Reisfeld, R.A., and Xiang, R. 2003. "Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEA-transgenic mice". **Vaccine** 21, 1938-1947.
118. Otten, G.R., Schaefer, M., Greer, C., Calderon-Cacia, M., Coit, D., Kazzaz, J., Medina-Selby, A., Selby, M., Singh, M., Ugozzoli, M., zur Megede, J., Barnett, S., O'Hagan, D., Donnelly, J., and Ulmer, J.B. 2003. "Induction of broad and potent anti-HIV immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed PLG microparticles". **J. Virol.** 77, 6087-6092.
119. zur Megede, J., Otten, G.R., Doe, B., Liu, H., Leung, L., Ulmer, J.B., Donnelly, J.D., and Barnett, S.W. 2003. "Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol, and gagpol DNA vaccines". **J. Virol.** 77, 6197-6207.
120. Donnelly, J.D., Berry, K., Ulmer, J.B. 2003. "Technical and regulatory hurdles for DNA vaccines". **Int. J. Parasitol.** 33, 457-467.
121. Ulmer, J.B. 2003. "The Future of Vaccines – Cancer Vaccines Meets Infectious Diseases" **IDrugs** 6, 525-526.
122. O'Hagan, D.T., Singh, M. and Ulmer, J.B. 2003. "Cationic microparticles and emulsions are effective delivery systems for immune stimulatory CpG DNA". In, **Cellular Drug Delivery: Principles and Practice**. Eds. R. Lu and S. Oie. Humana Press (Totowa, NJ). pp. 263-274.
123. Srivastava, I., Stamatatos, L., Kan, E., Lian, Y., Hilt, S., Martin L., Vita, C., Zhu, P., Roux, K.H., Vojtech, L., Wininger, M., Ulmer, J.B., and Barnett, S.W. 2003. "Purification, characterization and immunogenicity of a soluble trimeric envelope protein containing a

- partial deletion of the V2 loop derived from SF162, an R5-tropic HIV-1 isolate". **J. Virol.** 77, 11244-11259.
124. Valiante, N., O'Hagan, D.T. and Ulmer, J.B. 2003. "Innate immunity and biodefense vaccines". **Cell. Microbiol.** 5, 755-760.
125. Liu, M.A. and Ulmer, J.B. 2003. "Plasmid DNA technologies: Vaccines, gene therapy and beyond". **The Biochemist** 25, 21-24.
126. Barnett, S., Otten, G., Srivastava, I.K., zur Megede, J., Lian, Y., Schaefer, M., Liu, H., Deck, R., Donnelly, J., Polo, J., O'Hagan, D., Ulmer, J.B., Stamatatos, L., Montefiori, D., Lewis, M., Engelbrecht, S., van Ransburg, E.J., Widera, G. 2003. "Enhanced DNA prime-protein boost vaccines induce potent immune responses against HIV-1". In, **Retroviruses of Human AIDS and Related Animal Diseases**, XIII Cent Gardes Symposium, Eds M. Vicari, B. Dodet and M. Girard. Elsevier (New York, NY), pp.145-153.
127. Xu, F. and Ulmer, J.B. 2003. "Attenuated *Salmonella* and *Shigella* as carriers for DNA vaccines". **J. Drug Targeting** 11, 481-488.
128. Ulmer, J.B., Donnelly, J., and Gregersen, J.-P. 2004. "DNA vaccines: from research tools in mice to vaccines for humans". In **Pharmaceutical Biotechnology**, eds. O. Kayser, R. Muller. Wiley-VCH (Weinheim). pp. 79-102.
129. O'Hagan, D.T., Singh, M., and Ulmer, J.B. 2004. "Microparticles for Delivery of DNA Vaccines". **Immunol. Rev.** 199, 1-10.
130. Srivastava, I., Liu, M., and Ulmer, J.B. 2004. "DNA vaccines" In, **New Generation Vaccines**, 3rd edition, eds., Levine, M., Kaper, J.B., Rappuoli, R., Liu, M., Good, M.F. Marcel Dekker, Inc. (New York, NY) pp. 367-380.
131. Otten, G.R., Schaefer, M., Doe, B., Liu, H., Srivastava, I., zur Megede, J., O'Hagan, D., Donnelly, J.D., Widera, G., Rabussay, D., Lewis, M.G., Barnett, S.W., and Ulmer, J.B. 2004. "Enhancement of DNA vaccine potency in rhesus macaques by electroporation". **Vaccine** 22, 2489-2493.
132. Ulmer, J.B. 2004. "Enhancement of vaccine potency through improved delivery". **Exp. Opin. Biol. Therapy** 4, 1045-1053.
133. Srivastava, I.K., Ulmer, J.B., and Barnett, S.W. 2004. "Neutralizing antibody responses to HIV: role in protective immunity and challenges for vaccine design." **Expert Rev. Vaccines** 3, S33-S52.
134. Mollenkopf, H.J., Dietrich, G., Fensterle, J., Grode, L., Diehl, K.-D., Knapp, B., Singh, M., O'Hagan, D.T., Ulmer, J.B., and Kaufmann, S.H.E. 2004. "Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles". **Vaccine** 22, 2690-2695.
135. Mollenkopf, H.J., Grode, L., Mattow, J., Stein, M., Mann, P., Knapp, B., Ulmer, J.B., and Kaufmann, S.H.E. 2004. "Translation of mycobacterial proteomics to vaccine design: improved protection by BCG prime – Rv3407 DNA boost vaccination against tuberculosis." **Infect. Immunity** 72, 6471-6479.
136. Xie, H., Gursel, I., Ivins, B.E., O'Hagan, D.T., Ulmer, J.B., and Klinman, D.M. 2005. "CpG oligodeoxynucleotides adsorbed onto PLG microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine". **Infect. Immunity** 73, 828-833.
137. Pashine, A., Valiante, N.M., and Ulmer, J.B. 2005. "Targeting the innate immune response with improved vaccine adjuvants". **Nature Med.** 11, S63-S68.

138. Ulmer, J.B. 2005. "DNA Vaccines Forum – How to enhance the safety and potency of DNA vaccines?" **IDrugs**. 8, 357-359.
139. Otten, G.R., Schaefer, M., Doe, B., Liu, H., Srivastava, I., zur Megede, J., Kazzaz, J., Lian, Y., Singh, M., Ugozzoli, M., Montefiori, D., Lewis, M., Driver, D.A., Dubensky, T., Polo, J.M., Donnelly, J., O'Hagan, D., Barnett, S., Ulmer, J.B. 2005. "Enhanced potency of plasmid DNA/PLG microparticle HIV vaccines in rhesus macaques using a prime-boost regimen with recombinant proteins". **J. Virol.** 79, 8189-8200.
140. Denis-Mize, K., Singh, M., O'Hagan, D.T., Ulmer, J.B., and Donnelly, J.J. 2005. "Microparticles and DNA vaccines". In **Vaccine Adjuvants**, Hackett, C.J., Harn, D.A., eds., Humana Press, Totowa, NJ. pp. 257-270.
141. Srivastava, I., Ulmer, J.B., and Barnett, S.W. 2005. "Role of neutralizing antibodies in protective immunity against HIV". **Human Vaccines** 1, 45-60.
142. Song, M.-K., Vindurampulle, C., Capozzo, A.V.E., Ulmer, J.B., Polo, J., Pasetti, M.F., Barry, E.M., and Levine, M.M. 2005. "Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins". **J. Virol.** 79, 9854.
143. Lian, Y., Srivastava, I., Gomez-Roman, V.R., zur Megede, J., Sun, Y., Kan, E., Hilt, S., Engelbrecht, S., Himathongkham, S., Luciw, P.A., Otten, G., Ulmer, J.B., Donnelly, J.J., Rabussay, D., Montefiori, D., van Rensburg, E.J., and Barnett, S.W. 2005. "Evaluation of envelope vaccines derived from the South African subtype C HIV-1 TV1 strain". **J. Virol.** 79, 13338-13349.
144. Kong, W.-P., Xu, L., Stadler, K., Ulmer, J.B., Abrignani, S., Rappuoli, R., and Nabel, G.J. 2005. "Modulation of the immune response to the Severe Acute Respiratory Syndrome spike glycoprotein by gene-based and inactivated virus immunization". **J. Virol.** 79, 13915-13923.
145. Liu, M.A., and Ulmer, J.B. 2005. "Human clinical trials of plasmid DNA vaccines". In **Adv. Human Genetics**, J. Hall ed., Academic Press, vol. 55, pp. 25-40.
146. Barnett, S.W., Srivastava, I., Ulmer, J.B., Donnelly, J.J., and Rappuoli, R. 2005. "Development of V2-Deleted Trimeric Envelope Vaccine Candidates from Human Immunodeficiency Virus type 1 (HIV-1) Subtypes B and C". **Microbes and Infection** 7, 1386-1391.
147. Rappuoli, R., and Ulmer, J.B. 2005. "DNA vaccination". **Current Protocols in Human Genetics**, eds. N.C. Dracopoli, J.L. Haines, B.R. Korf, C.C. Morton, C.E. Seidman, J.G. Seidman, D.R. Smith, John Wiley & Sons. Unit 13.2.
148. zur Megede, J., Otten, G.R., Doe, B., Liu, H., Srivastava, R., Greer, C.E., Legg, H., Polo, J.M., Donnelly, J.J., Ulmer, J.B., and Barnett, S.W. 2006. "Evaluation of human immunodeficiency virus type I subtype C gag, pol and gagpol DNA and alphavirus replicon vaccines". **Vaccine** 24, 2755-2763.
149. Otten, G.R., Schaefer, M., Doe, B., Liu, H., zur Megede, J., Donnelly, J., Rabussay, D., Barnett, S.W., and Ulmer, J.B. 2006. Potent immunogenicity of an HIV-1 *gag-pol* fusion DNA vaccine delivered by *in vivo* electroporation. **Vaccine** 24, 4503-4509.
150. Ulmer, J.B., Wharen, B., and Liu, M.A. 2006. "Gene-based vaccines: recent technical and clinical advances". **Trends Mol. Med.** 12, 216-222.
151. Pashine, A., Ulmer, J.B. and Valiante, N.M. 2006. "Innate immune mechanisms and the identification of immune potentiators as vaccine adjuvants". In, **Immune Potentiators in Modern Vaccines** (Virgil E.C.J.Schijns, ed. Academic Press), pp. 57-72.

152. Capozzo, A.V., Polo, J.M., Ulmer, J.B., Barry, E.M., Levine, M.M., and Pasetti, M.F. 2006. "Neonatal immunization with a Sindbis-DNA measles vaccine induces adult-like neutralizing antibodies and cell-mediated immunity in the presence of maternal antibodies." **J. Immunol.** 176, 5671-5681.
153. Sharma, V.A., Kan, E., Sun, Y., Lian, Y., Cisto, J., Hilt, S., Wininger, M.T., Stamatatos, L., Donnelly, J.J., Ulmer, J.B., Barnett, S.W., and Srivastava, I.K. 2006. "Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines". **Viol.** 352, 131-144.
154. Ulmer, J.B. 2006. "Novel Vaccines: Bridging Research, Development and Production ". **IDrugs.** 9, 696-698.
155. O'Hagan, D.T., Singh, M., and Ulmer, J.B. 2006. "Microparticle-based technologies for vaccines". **Methods** 40, 10-19.
156. Ulmer, J.B., Valley, U., and Rappuoli, R. 2006. "Vaccine manufacturing: Challenges and solutions". **Nature Biotechnol.** 24, 1377-1383.
157. Ulmer, J.B., Wharen, B., and Liu, M.A. 2006. "DNA vaccines: recent technical and clinical advances". **Discovery Medicine** 6, 109-112.
158. Srivastava, I.K., Kan, E., Sun, Y., Legg, H., Lee, Q., Burke, B., Greer, C., Lian, Y., Stamatatos, L., Ulmer, J.B., Vajdy, M., Donnelly, J., Miller, C., and Barnett, S.W. 2006. "Antibody mediated protection of immunized macaques against pathogenic SHIV challenge. **Retroviol.** 3, S27.
159. Ulmer, J.B., Wharen, B., and Liu, M.A. 2006. "DNA vaccines for HIV AIDS". **Curr. Opin. HIV AIDS** 1, 309-313.
160. Xu, F., Valiante, M., and Ulmer, J.B. 2007. "Small molecule immune potentiators as vaccine adjuvants". In **Vaccine Adjuvants and Delivery Systems**. Wiley-Interscience, M. Singh ed. pp. 175-190.
161. Salenius, K., Simard, N., Harland, R., and Ulmer, J.B. 2007. "The road to licensure of a DNA vaccine". **Curr. Opin. Invest. Drugs** 8, 635-641.
162. Pasetti, M.F., Resendiz-Albor, A., Ramirez K., Stout, R., Papania, M., Adams, R.J., Polack, F.P., Ward, B.J., Burt, D., Chabot, S., Ulmer, J., Barry, E.M., and Levine, M.M. 2007. "Heterologous prime boost strategy to immunize very young infants against measles: pre-clinical studies in rhesus macaques". **Clin. Pharm. Therapeutics** 82, 672-685.
163. Weiss, W.R., Kumar, A., Jiang, G., Bostick, A., Conteh, S., Fryauff, D., Aguiar, J., Singh, M., O'Hagan, D.T., Ulmer, J.B., and Richie, T.L. 2007. "Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens". **PloS ONE** 10, e1063.
164. Rappuoli, R. and Ulmer, J.B. 2007. "Vaccines research and development: Poised for rapid growth". **Curr. Opin. Biotechnol.** 18, 521-523.
165. Ulmer, J.B. and Donnelly, J.J. 2007. "DNA vaccines". **Encyclopedia Life Sci.** (on-line at <http://www.els.net>).
166. Srivastava, I.K., Kan, E., Sun, Y., Sharma, V.A., Cisto, J., Burke, B., Lian, Y., Hilt, S., Biron, Z., Hartog, K., Stamatatos, L., Cheng, R.H., Ulmer, J.B., and Barnett, S.W. 2008. "Comparative evaluation of trimeric envelope glycoproteins derived from subtype C and B HIV-1 R5 isolates". **Viol.** 372, 273-290.
167. Ulmer, J.B. 2008. "DNA Vaccines: Bridging the gap between technology and application ". **IDrugs.** 11, 322-324.

168. Ramirez, K., Ulmer, J.B., Stout, R., Barry, E.M., Levine, M.M., and Pasetti, M.F. 2008. "Preclinical safety and biodistribution of Sindbis virus measles DNA vaccines administered as a single dose or followed by the live attenuated measles vaccine in a prime-boost regimen". **Human Gene Ther.** 19, 522-531.
169. Ulmer, J. 2008. "A true vaccine pioneer". Book review of "Vaccinated: One man's quest to defeat the world's deadliest diseases." **Nature Med.** 14, 113.
170. zur Megede, J., Sanders-Beer, B., Silvera, P., Golightly, D., Bowlsbey, A., Hebblewaite, D., Sites, D., Nieves-Duran, L., Srivastava, R., Otten, G.R., Rabussay, D., Zhang, L., Ulmer, J.B., Barnett, S.W., and Donnelly, J.J. 2008. "A therapeutic SIV DNA vaccine elicits T-cell immune responses, but no sustained control of viremia in SIVmac239-infected rhesus macaques". **AIDS Res Human Retroviruses** 24, 1103-1116.
171. Dormitzer, P.R., Ulmer, J.B., and Rappuoli, R. 2008. "Structure-based antigen design: A strategy for next-generation vaccines". **Trends Biotechnol.** 26, 659-667.
172. Martin, G., Sun, Y., Heyd, B., Combes, O., Ulmer, J.B., Descours, A., Barnett, S.W., Srivastava, I.K., and Martin, L. 2008. "A simple one-step method for the preparation of HIV-1 envelope glycoprotein immunogens based on a CD4 mimic peptide." **Viol.** 381, 241-250.
173. Burke, B., Gomez-Roman, V.R., Lian, Y., Sun, Y., Kan, E., Ulmer, J., Srivastava, I.K., and Barnett, S.W. 2009. "Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits." **Viol.** 387, 147-156.
174. Pasetti, M.F., Ramirez, K., Resendiz-Albor, A., Ulmer, J., Barry, E.M., and Levine, M.M. 2009. "Sindbis virus-based measles DNA vaccines protect cotton rats against respiratory measles: relevance of antibodies, mucosal and systemic antibody-secreting cells, memory B cells, and Th1-type cytokines as correlates of immunity." **J. Virol.** 83, 2789-2794.
175. Nabel, G.J., Kaslow, D.C., Ulmer, J.B. and Liu, M.A. 2009. "DNA vaccines." In, **New Generation Vaccines 4th Edition**, eds., Levine, Myron M., Woodrow, Graeme C., Kaper, James B. and Cobon, Gary S., Marcel Dekker, Inc. (New York, NY) (in press).

PATENTS

1. Polynucleotide tuberculosis vaccine, US 5,736,524.
2. Polynucleotide tuberculosis vaccine, US 6,384,018.

INVITED PRESENTATIONS (past 5 years)

IIR Conference on Vaccines Clinical Trials (London, UK), 1/27/03.
3rd Cabo Gene Therapy Focus Panel (Cabo San Lucas, Mexico), 2/15/03.
World Vaccine Congress (Montreal, Canada), 4/9/03.
The Future of Vaccines – Cancer Meets Infectious Diseases (Semmering, Austria), 4/12/03.
Modern Vaccine Adjuvants & Delivery Systems (Dublin, Ireland), 6/6/03.
HIV Vaccines – Design, Potency & Delivery (Boston, MA), 6/22/03.
BIO 2003 (Washington, DC), 6/24/03.
Society for General Microbiology (UMIST, Manchester, UK), 9/10/03.

Tuberculosis Vaccines for the World Conference (Montreal, Canada), 9/19/03.
6th International Forum on Global Vaccinology (Minsk, Belarus), 9/25/03.
Fondacion Valenciana de Estudios Avanzados “Genetic Intervention in Disease” (Valencia, Spain), 11/27/03.
The Viability of DNA Vaccines Forum (London, UK), 1/4/04.
WHO Meeting on Development of Influenza Vaccines (Geneva, Switzerland), 2/27/04.
Phacilitate Vaccine Forum (Amsterdam, Netherlands), 5/10/04.
American Society for Gene Therapy (Minneapolis, MN), 6/5/04.
Controlled Release Society (Honolulu, HI), 6/16/04.
University of Pennsylvania Center for AIDS Research seminar series (Philadelphia, PA), 9/16/04.
Emerging Infections and New Vaccinations (Marburg, Germany), 9/28/04.
Phacilitate Vaccine Forum (Boston, MA), 11/2/04.
DNA Vaccines (Monte Carlo, Monaco), 11/18/04.
DNA Vaccines (London, UK), 3/17/05.
3rd International Workshop on DNA Vaccines (Brno, Czech Republic), 5/26/05.
American Society for Gene Therapy (St. Louis, MO), 6/1/05.
Infocast Conference on Innate Immunity to Vaccines (San Diego, CA), 6/14/05.
WHO Consultation on Revision of the WHO Guidelines on DNA Vaccines (Geneva, Switzerland), 7/4/05.
Innate Immunity in the 21st Century (Lansdowne, VA), 9/27/05.
Vaccine Potency (Bethesda, MD), 10/10/05.
Vaccines: All Things Considered (Alexandria, VA), 11/3/05.
Phacilitate Vaccines Forum 2006 (Baltimore, MD), 1/30/06.
Marcus Evans DNA Vaccine Forum (London, UK), 3/16/06.
4th International Workshop on DNA Vaccines (Trest, Czech Republic), 5/3/06.
SMI Conference Vaccines: Bench to Bedside (London, UK), 5/22/06.
CHI Conference on Novel Vaccines: Bridging Research, Development and Production (Cambridge, MA), 8/21/06.
ICWO Vaccine Conference (Montreal, Canada), 11/9/06.
Phacilitate Vaccines Forum 2007 (Baltimore, MD), 1/23/07.
DNA Vaccines (Malaga, Spain), 5/25/07.
Innate Crossroads, Aegean Conferences (Crete, Greece), 6/18/07.
CHI Conference on Novel Vaccines (Cambridge, MA), 8/23/07.
NIH Conference on SARS: Current Progress, Future Directions (Bethesda, MD), 10/1/07.
Suddath Symposium on Drug Design, Development and Delivery (Atlanta, GA), 3/7/08.
Marcus Evans Conference on DNA Vaccines (London, UK), 3/10/08.
Vaccine Technologies II (Albufeira, Portugal), 6/2/08.
CHI Conference on Novel Vaccines (Cambridge, MA) 8/14/08.
Strathclyde Institute of Pharmacy and Biomedical Sciences (Glasgow, Scotland), 10/28/08.
International Society for DNA Vaccines (Las Vegas, NV), 12/10/08.
Massachusetts Institute of Technology, Department of Chemical Engineering (Cambridge, MA), 3/10/09.

Biotechnology Industry Organization Annual Meeting (Atlanta, GA), 5/20/09.

SCIENTIFIC ADVISORY BOARDS and COMMITTEES

Duke University Program on Multiscale Systems Immunology for Adjuvant Development.

North Dakota High Throughput Vaccinology Initiative.

VGX/University of Pennsylvania Design and Development Team Program.

University of Chicago Toxoplasmosis Vaccine Program.

Infectious Disease Committee, American Society of Gene Therapy.

Gene-Based Vaccines Committee, American Society of Gene Therapy.

Global HIV Vaccine Enterprise Working Group on Immunogens and Antigen Processing.

EDITORIAL BOARDS

Expert Opinion on Biological Therapy

Human Vaccines

AD HOC REVIEWER

Antisense and Nucleic Acid Drug Development

Atlantic Genome Centre Peer Review Panel

Austrian Science Foundation

Clinical Microbiology Reviews

Expert Opinion on Investigational Drugs

Expert Review of Anti-Infective Therapy

Gene Therapy

Genome Canada

Human Gene Therapy

Immunity

Immunology Today

Infection and Immunity

International Immunology

Israel Science Foundation

Journal of Clinical Investigation

Journal of Controlled Release

Journal of Experimental Medicine

Journal of Gene Medicine

Journal of General Virology

Journal of Immunological Methods

Journal of Immunology

Journal of Pharmaceutical Sciences

Medical Research Council of Canada

Molecular Medicine

Molecular Therapy

Natural Sciences and Engineering Research Council of Canada

Nature

Nature Biotechnology

Nature Immunology

Nature Medicine
Nature Reviews on Drug Discovery
New York Academy of Sciences
NIAID Joint Ventures in Biomedicine and Biotechnology Challenge Grants Program
Novartis Foundation
Office of Naval Research, Independent Research Program
Pharmaceutical Research
Proceedings of the National Academy of Sciences
Science
Trends in Microbiology
USDA National Research Initiative Competitive Grants Program
Wellcome Trust
Vaccine
Veterinary Microbiology